|
|
Vaccine Detail
|
Synthetic Peptides E-PRA And E-PSM Vaccine |
| Vaccine Information |
- Vaccine Name: Synthetic Peptides E-PRA And E-PSM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007046
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- S100A6
gene engineering:
- Type: Recombinant protein preparation
- Description: (Weber et al., 2011)
- Detailed Gene Information: Click Here.
- Preparation: pPRA-PSM is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA, formulated as a sterile aqueous solution at a concentration of 4.0 mg/mL. The plasmid insert was engineered as a “string-of-beads” to yield the epitopes PRAME 425–433 and PSMA 288–297. In addition, the plasmid contained the sequences corresponding to PRAME antigen fragment 422–509 and PSMA antigen fragments 3–45 and 217–297 (Weber et al., 2011).
- Description: This is for various cancers (NCT00423254). A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MElanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may stimulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated antigens upregulated and expressed on the cell surfaces of certain tumor cell types (NCIT_C67098; Weber et al., 2011).
|
| Host Response |
|
|
| References |
NCIT_C67098: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67098]
NCT00423254: [https://clinicaltrials.gov/show/NCT00423254/]
Weber et al., 2011: Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. Journal of immunotherapy (Hagerstown, Md. : 1997). 2011; 34(7); 556-567. [PubMed: 21760528].
|
|
